Rockwell Medical (Nasdaq: RMTI) 14.2% LOWER; summarized findings from its completed Phase IIb clinical study. The study evaluated Soluble Ferric Pyrophosphate, the Company’s proprietary investigational product for continuous iron maintenance therapy in chronic hemodialysis patients. Click here for the full report.

CROCS Inc. (Nasdaq: CROX) 14% LOWER; reports Q4 adjusted loss of $0.04, versus the analyst estimate of ($0.13). Revenue for the quarter was $136 million, which compares to the estimate of $117.21 million. Sees Q110 EPS break even, compared to ($0.01). And Q110 sales of $155 - $160 million, versus $148.2 million consensus.

Rosetta Stone Inc. (NYSE: RST)